The Partnership for Patients (PfP) and the Agency for Healthcare Research and Quality (AHRQ) have reported a 23.5% decline in hospital-acquired pressure ulcers (HAPU) over 4 years resulting in a cumulative cost savings of more than $10 billion and 49 000 averted deaths, claiming that this significant decline may have been spurred in part by Medicare payment incentives associated with severe (stage 3 or 4) HAPUs. Hospitals with a high rate of severe HAPUs have a payment penalty imposed, creating a financial disincentive to report severe HAPUs, possibly contributing to the magnitude of the reported decline. Despite the financial disincentive to report, the number of severe HAPUs found in claims data over the corresponding 4-year period did not decline but instead remained unchanged. The results from claims data, combined with some flaws in estimating HAPUs, call into question the validity of the decline in HAPUs reported by PfP and AHRQ.
In September 2015, the Partnership for Patients (PfP), 1 a public-private initiative led by the Centers for Medicare & Medicaid Services (CMS) received $1.1 billion in Affordable Care Act funding to continue its work in reducing preventable hospital-acquired conditions and readmissions. 2 Since 2011, PfP and the Agency for Healthcare Research and Quality (AHRQ) have together published a national scorecard on rates of hospitalacquired conditions. In December 2015, the latest scorecard reported a 17% reduction in the total number of hospital-acquired conditions under surveillance, resulting in a cumulative cost savings of $19.8 billion, and 87 000 deaths averted. The largest single contributor to these improvements was a reduction in the number of hospitalacquired pressure ulcers (HAPUs), from 1.32 million in the baseline year of 2010 to 1.01 million in 2014, an estimated reduction of 310 000 fewer HAPUs in 2014 than would have been expected-a 23.5% decline. The cumulative reduction in HAPUs across the 4-year time period was estimated to result in cost savings of more than $10 billion, and 49 000 averted deaths.
In support of these significant declines in a relatively short time period, PfP and AHRQ explained that, Although the precise causes of the decline in patient harm are not fully understood, the increase in safety has occurred during a period of concerted attention by hospitals throughout the country to reduce adverse events. This effort has been spurred in part by Medicare payment incentives and catalyzed by the US Department of Health and Human Services Partnership for Patients (PfP) initiative. 3 If these dramatic improvements are accurate, then it is certainly reasonable to assume that the Medicare payment incentives aimed at lowering inpatient complications "spurred" some of the reported reductions in HAPUs. The purpose of this study is to use claims data to examine whether these estimates of HAPU reductions and the associated cost savings are in fact reasonable and accurate.
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The estimated 23.5% decline in HAPUs and the associated cost savings of more than $10 billion between 2010 and 2014 were derived from the Medicare Patient Safety Monitoring System (MPSMS) chart reviews of a limited subset of Medicare patients varying between 18 000 and 33 000 patients in a given year. 6 It could be argued that chart reviews produce more accurate data on HAPUs than is reported in claims data. Although there is some merit to that argument for HAPUs that do not impact payment (stage 1, stage 2, and stage unspecified HAPUs), it is unlikely to be true for stage 3 and stage 4 HAPUs that directly impact payment. If the decline in stage 3 and stage 4 HAPUs derived from the MPSMS chart reviews was accurate, the lack of an actual decline in the claims data would imply that hospitals are systematically overreporting stage 3 and stage 4 HAPUs. Overreporting of stage 3 and stage 4 HAPUs by hospitals seems very unlikely in light of the financial disincentive to report them. As a result, the decline in HAPU rates reported by AHRQ and PfP are at least counterintuitive and at best questionable.
The rate of HAPUs for Medicare patients, derived from the MPSMS reviews, was used to estimate the number of HAPUs in the overall populations even though the HAPU rate for patients younger than age 65 is much lower than for patients ages 65 and older. Previous studies have found that only 30% of HAPUs occur in the population younger than age 65. 7 Simply recalculating to accommodate for these differences in age-related rates would reduce the HAPU rate for the overall population by almost half. Indeed, the authors of the AHRQ and PfP study admitted that "it is possible that the ratios we estimated with those data are not correct for all patients." 8 Similarly the estimated $17 286 cost of a HAPU used in AHRQ and PfP estimates was based on a study of stage 3 and stage 4 HAPUs but applied to all HAPUs regardless of stage, thereby including the less costly stage 1, stage 2, and non-staged HAPUs. 9 Because stage 3 and stage 4 ulcers make up at most 25% of all HAPUs, an inflated cost estimate was applied to the large majority of HAPU cases. 7 The combined effect of using an inflated cost estimate applied to an inflated number of HAPUs means that the AHRQ estimated cost savings are dramatically overstated. Indeed, if the decline in HAPUs was based on claims data instead of the MPSMS chart reviews, the estimated savings associated with stage 3 and stage 4 HAPUs would be virtually zero. This conclusion is consistent with a study done by Mathematica Policy Research, which found that estimates of HAPU reductions using other data sources were minimal or nonexistent. 10 Perhaps most troubling is that the results reported by AHRQ and PfP could be used as the basis for future policy initiatives under the assumption that substantial improvements in quality and efficiency have actually been achieved. The results reported by AHRQ and PfP have generated significant press coverage, creating an unjustified sense of confidence in the effectiveness of the PfP program. 11 The substantial investment of more than $1.1 billion made by CMS in the PfP program certainly merits a thorough and valid evaluation. The fact that the reported results are so inconsistent with the claims data and at odds with the expectations generated by the existing payment incentives requires explanation. Furthermore, the questionable assumptions made in the process of extrapolating Medicare results to the general population needs scrutiny and correction. The authors agree with others who have called for a more considered and transparent framework within which to assess the contributions of the PfP initiative and the hospital engagement networks. 
